Get the Stockscreener App
18.44
0.38%
0.07
Pre-market:
18.50
0.06
+0.33%
Dyne Therapeutics Inc stock is traded at $18.44, with a volume of 979.94K.
It is up +0.38% in the last 24 hours and down -2.95% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$18.37
Open:
$18.435
24h Volume:
979.94K
Relative Volume:
0.49
Market Cap:
$3.05B
Revenue:
-
Net Income/Loss:
$-446.21M
P/E Ratio:
-5.204
EPS:
-3.5434
Net Cash Flow:
$-423.92M
1W Performance:
-2.12%
1M Performance:
-2.95%
6M Performance:
-2.07%
1Y Performance:
+52.40%
1-Day Range:
$18.19
$18.68
1-Week Range:
$17.32
$18.95
52-Week Range:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
18.44 | 3.04B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
453.06 | 113.78B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
719.88 | 75.84B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.70 | 50.55B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.48 | 38.99B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
316.55 | 32.69B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics (DYN) upgraded to buy: Here's what you should know - MSN
Form 144 filed on restricted stock units for DYN (NASDAQ: DYN) - Stock Titan
DYN (Nasdaq) insider resale of 5,727 shares; 4,062 RSUs granted - Stock Titan
Dyne Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Clinical-stage Dyne Therapeutics lines up three healthcare investor events - Stock Titan
Responsive Playbooks and the DYN Inflection - Stock Traders Daily
Dyne Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
DYN SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Impact of FDA Leadership Changes on Dyne Therapeutics (DYN) - GuruFocus
Dyne Therapeutics: Runway To Fund Operations Into 1Qf 2028 >DYN - Moomoo
Dyne Therapeutics, Inc. Q1 2026 10-Q Report: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Dyne Therapeutics (DYN) Advances Towards Z-Rostudirsen Launch in DMD - GuruFocus
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know - sharewise.com
Dyne Therapeutics Q1 Net Loss Narrows - Moomoo
Dyne Therapeutics Reports Positive Q1 2026 Results: Advancing DMD & DM1 Programs Toward FDA Approval and Commercial Launch - Minichart
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights - Investing News Network
Dyne Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Dyne Therapeutics 1Q Loss $120.9M >DYN - Moomoo
Earnings Flash (DYN) Dyne Therapeutics Posts Q1 Loss $0.73 a Share, vs. FactSet Est of $0.74 Loss - marketscreener.com
Dyne Therapeutics (NASDAQ: DYN) details DMD and DM1 trial progress - Stock Titan
Dyne Therapeutics 1Q 2026: Net loss $(120.9M), EPS $(0.73) — 10-Q Summary - TradingView
Dyne targets potential 2027-28 launches for two muscle drugs - Stock Titan
Dyne Therapeutics (DYN) deepens R&D spend with $120.9M loss, $972M cash runway - Stock Titan
MSN Money - MSN
Number of shareholders of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Changes Afoot at FDA: Impact on Dyne Therapeutics (DYN) - GuruFocus
Dyne Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Dyne therapeutics director Jason Rhodes sells $1.9m in shares By Investing.com - Investing.com India
Dyne therapeutics director Jason Rhodes sells $1.9m in shares - Investing.com
Atlas funds trim Dyne Therapeutics (DYN) stake in planned stock sales - Stock Titan
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
FMR LLC reports 5.4% stake in Dyne Therapeutics (NASDAQ: DYN) in Schedule 13G - Stock Titan
Wall Street Zen Downgrades Dyne Therapeutics (NASDAQ:DYN) to Strong Sell - MarketBeat
Understanding the Setup: (DYN) and Scalable Risk - Stock Traders Daily
DYN Stock Chart | DYNE THERAPEUTICS INC (NASDAQ:DYN) - ChartMill
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
3.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):